Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Post by GrahamBon May 31, 2023 12:08pm
91 Views
Post# 35472720

What was said, What Happened?

What was said, What Happened?

What was said

 

6 purchases have been made year to date and 5 more expected by the end of January to add to the 29 deployed VMS+ units to achieve 40 committed units

 

The Company has aggressively marketed its VMS+ products at 12 medical conferences this year and engaged hundreds of clinicians.  The Company had set a target of 40-45 systems committed to customers by year end.  The company has received 6 purchase orders year to date, including orders from Europe, UK, and United States, has 3 installations being arranged and 5 more purchase orders are expected by end of January.

 

What happened:

 

3,890 sales in Q1

 

1,344,888 is the Total loss in the Quarter 

 

OK bact to facts:

Sales….

 

JUST FOR CONTEXT 

 

Total revenue for year ending Dec. 31, 2021  = ZERO

 

Total revenue for year ending Dec. 31, 2020  = $36,017

 

Total revenue for year ending Dec. 31, 2019  = $81,023

 

Total revenue for year ending Dec. 31, 2018  = $60,177

 

ALL DATA FROM SEDAR.COM

<< Previous
Bullboard Posts
Next >>